CREVECOEUR, Julie ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
Kaminski, RM
Rogister, Bernard ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
Foerch, P
Vandenplas, C
Neveux, M
Mazzuferi, M
KROONEN, Jérôme ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
Poulet, Christophe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
MARTIN, Didier ; Centre Hospitalier Universitaire de Liège - CHU > Neurochirurgie
SADZOT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
RIKIR, Estelle ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Klitgaard, H
MOONEN, Gustave ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Deprez, Manuel ; Université de Liège - ULiège > Département des sciences cliniques > Neuropathologie
Janz R, Goda Y, Geppert M, Missler M, Südhof TC. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 1999; 24: 1003-1016
Hayashi M, Yamamoto A, Yatsushiro S, Yamada H, Futai M, Yamaguchi A, Moriyama Y. Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. J Neurochem 1998; 71: 356-365
Dardou D, Dassesse D, Cuvelier L, Deprez T, De Ryck M, Schiffmann SN. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res 2011; 1367: 130-145
Janz R, Südhof TC. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 1999; 94: 1279-1290
Gronborg M, Pavlos NJ, Brunk I, Chua JJ, Munster-Wandowski A, Riedel D, Ahnert-Hilger G, Urlaub H, Jahn R. Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J Neurosci 2010; 30: 2-12
Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-596
Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006; 536: 102-108
van Vliet EA, Araújo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-534
Klitgaard H, Verdu P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov 2007; 2: 1537-1545
Matagne A, Margineanu D-G, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662-1671
Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 1999; 96: 15268-15273
Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720
Gorter JA, van Vliet EA, Aronica E, Breit T, Rauwerda H, Lopes da Silva FH, Wadman WJ. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006; 26: 11083-11110
De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev 2007; 13: 43-56
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 9861-9866
Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O'Rourke D, Doherty CP, Shianna KV, Wood NW, Sander JW, Delanty N, Goldstein DB, Sisodiya SM. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res 2009; 83: 44-51
van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 2009; 50: 422-433
Wang MM, Janz R, Belizaire R, Frishman LJ, Sherry DM. Differential distribution and developmental expression of synaptic vesicle protein 2 isoforms in the mouse retina. J Comp Neurol 2003; 460: 106-122
Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R. SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 2010; 66: 884-895
Iezzi M, Theander S, Janz R, Loze C, Wollheim CB. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J Cell Sci 2005; 118: 5647-5660
Yang W, Maqsodi B, Ma Y, Bui S, Crawford KL, McMaster GK, Witney F, Luo Y. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques 2006; 40: 481-486
Tsongalis GJ. Branched DNA technology in molecular diagnostics. Am J Clin Pathol 2006; 126: 448-453
Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK, Kristal AR. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn 2008; 10: 169-176
Lynoë N, Sandlund M, Dahlgvist G, Jacobsson L. Declaration of Helsinki. Br Med J 1991; 302: 1194
Blümcke I, Pauli E, Clusmann H, Schramm J, Becker A, Elger C, Merschhemke M, Meencke H-J, Lehmann T, von Deimling A, Scheiwe C, Zentner J, Volk B, Romstöck J, Stefan H, Hildebrandt M. A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol (Berl) 2007; 113: 235-244
Miyauchi N, Saito A, Karasawa T, Harita Y, Suzuki K, Koike H, Han GD, Shimizu F, Kawachi H. Synaptic vesicle protein 2B is expressed in podocyte, and its expression is altered in proteinuric glomeruli. J Am Soc Nephrol 2006; 17: 2748-2759
Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291-299
Danscher G, Stoltenberg M, Bruhn M, Søndergaard C, Jensen D. Immersion autometallography: histochemical in situ capturing of zinc ions in catalytic zinc-sulfur nanocrystals. J Histochem Cytochem 2004; 52: 1619-1625
Károly N, Mihály A, Dobó E. Comparative immunohistochemistry of synaptic markers in the rodent hippocampus in pilocarpine epilepsy. Acta Histochem 2011; 113: 656-662
Proper EA, Oestreicher AB, Jansen GH, Veelen CW, van Rijen PC, Gispen WH, de Graan PN. Immunohistochemical characterization of mossy fibre sprouting in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2000; 123 (Pt 1): 19-30
Sloviter R. A simplified Timm stain procedure compatible with formaldehyde fixation and routine paraffin embedding of rat brain. Brain Res Bull 1982; 8: 771-774
R Core Team. R: a language and environment for statistical computing. 2012 [cited; R Foundation for Statistical Computing]. Available at: http://www.R-project.org/ (last accessed 11 January 2013)
de Groot M, Toering ST, Boer K, Spliet WGM, Heimans JJ, Aronica E, Reijneveld JC. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro-oncol 2010; 12: 265-273
Thom M, Sisodiya S, Najm I. Neuropathology of epilepsy. In Greenfield's Neuropathology, 8th edn. Eds S Love, DN Louis, DW Ellison. London: Hodder Arnold, 2008; 833-887
Amaral D, Lavenex P. Hippocampal neuroanatomy. In The Hippocampus Book. Eds P Andersen, R Morris, D Amaral, T Bliss, J O'Keefe. New York: Oxford University Press, 2007; 37-114
Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci U S A 1996; 93: 14934-14939
Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WGM, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 2009; 50: 1409-1418
de Groot M, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 2011; 77: 532-539
Wan QF, Vila A, Zhou ZY, Heidelberger R. Synaptic vesicle dynamics in mouse rod bipolar cells. Vis Neurosci 2008; 25: 523-533
Babb TL, Kupfer WR, Pretorius JK, Crandall PH, Levesque MF. Synaptic reorganization by mossy fibers in human epileptic fascia dentata. Neuroscience 1991; 42: 351-363
Amano S, Ikeda M, Uemura S, Fukuoka J, Tsuji A, Sasahara M, Hayase Y, Hazama F. Mossy fiber sprouting in the dentate gyrus in a newly developed epileptic mutant, Ihara epileptic rat. Brain Res 1999; 834: 214-218
Laurberg S, Zimmer J. Lesion-induced sprouting of hippocampal mossy fiber collaterals to the fascia dentata in developing and adult rats. J Comp Neurol 1981; 200: 433-459
Doering P, Danscher G, Larsen A, Bruhn M, Søndergaard C, Stoltenberg M. Changes in the vesicular zinc pattern following traumatic brain injury. Neuroscience 2007; 150: 93-103
Wieser HG, Blume WT, Fish D, Goldensohn E, Hufnagel A, King D, Sperling MR, Lüders H, Pedley TA, (ILAE) CoNotILAE. ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia 2001; 42: 282-286
